Nedaplatin

    
98%

Nedaplatin

源叶(MedMol)
S81166 一键复制产品信息
95734-82-0
C2H8N2O3Pt
303.17
顺糖氨铂;奈达铂
货号 规格 价格 上海 北京 武汉 南京 购买数量
S81166-10mg 98% ¥69.00 6 - - -
S81166-50mg 98% ¥245.00 6 - - -
S81166-100mg 98% ¥425.00 2 - - -
S81166-250mg 98% ¥595.00 3 - - -
S81166-1g 98% ¥1700.00 货期:2-3天 - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品

产品介绍

The inhibition of cell (including human SCLC cell line SBC-3 and human NSCLC cell line PC-14) proliferation after drug treatments as the antitumor activity using a regrowth assay is messured. Briefly, cells are exposed to drugs alone or in combination for 6 days at 37°C in an atmosphere of 100% humidity with 5% CO2; the cells are then pipetted six to eight times until almost all cells appeared as single cells and counted with a counter. For each drug, concentration-effect curves are drawn as plots of the fraction of surviving cells (unaffected cell fraction, fu) versus drug concentration. The cell proliferation ratio of the treated:control cultures (T:C%) is calculated as follows: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. The IC50 is defined as the drug concentration required for a 50% reduction in the number of cells. Four or five independent experiments are carried out for each. To check the effect of the drug treatment schedule on the effect of the combination, the cells are treated either by simultaneous exposure to the two drugs or by sequential exposure to Nedaplatin followed by irinotecan (Nedaplatin→irinotecan) and vice versa (irinotecan→Nedaplatin) for 3 hours. For the sequential exposure treatment, cells are exposed to the first drug for 3 hours, ished in fresh medium once, and then immediately exposed to the second drug for 3 hours. The treated cells are cultured in drug-free medium until evaluation.(Only for Reference)

产品描述: The inhibition of cell (including human SCLC cell line SBC-3 and human NSCLC cell line PC-14) proliferation after drug treatments as the antitumor activity using a regrowth assay is messured. Briefly, cells are exposed to drugs alone or in combination for 6 days at 37°C in an atmosphere of 100% humidity with 5% CO2; the cells are then pipetted six to eight times until almost all cells appeared as single cells and counted with a counter. For each drug, concentration-effect curves are drawn as plots of the fraction of surviving cells (unaffected cell fraction, fu) versus drug concentration. The cell proliferation ratio of the treated:control cultures (T:C%) is calculated as follows: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. The IC50 is defined as the drug concentration required for a 50% reduction in the number of cells. Four or five independent experiments are carried out for each. To check the effect of the drug treatment schedule on the effect of the combination, the cells are treated either by simultaneous exposure to the two drugs or by sequential exposure to Nedaplatin followed by irinotecan (Nedaplatin→irinotecan) and vice versa (irinotecan→Nedaplatin) for 3 hours. For the sequential exposure treatment, cells are exposed to the first drug for 3 hours, ished in fresh medium once, and then immediately exposed to the second drug for 3 hours. The treated cells are cultured in drug-free medium until evaluation.(Only for Reference)
靶点: DNA/RNA Synthesis;DNA/RNASynthesis
体内研究: Nedaplatin (Aqupla)是顺铂衍生物,能抑制肿瘤克隆集落形成(IC50:28.5 μg/mL)。0.005-0.5 μg/mL的Nedaplatin对SBC-3细胞增殖的抑制效果为2%-98%(IC50:0.053 μg/mL)
细胞实验: The inhibition of cell (including human SCLC cell line SBC-3 and human NSCLC cell line PC-14) proliferation after drug treatments as the antitumor activity using a regrowth assay is messured. Briefly, cells are exposed to drugs alone or in combination for 6 days at 37°C in an atmosphere of 100% humidity with 5% CO2; the cells are then pipetted six to eight times until almost all cells appeared as single cells and counted with a counter. For each drug, concentration-effect curves are drawn as plots of the fraction of surviving cells (unaffected cell fraction, fu) versus drug concentration. The cell proliferation ratio of the treated:control cultures (T:C%) is calculated as follows: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. The IC50 is defined as the drug concentration required for a 50% reduction in the number of cells. Four or five independent experiments are carried out for each. To c
参考文献: 1.Alberts DS, et al. Cancer Chemother Pharmacol, 1997, 39(6), 493-497. 2.Matsumoto M, et al. Jpn J Cancer Res, 2001, 92(1), 51-58. 3.Kanzawa F, et al. Clin Cancer Res, 2001, 7(1), 202-209. 4.Wheate NJ et al. Dalton Trans, 2010, 39(35), 8113-8127. 5.Uchida N, et al.Eur J Cancer, 1998, 34(11), 1796-1801.
溶解性: DMSO:Insoluble    H2O:10  mM
保存条件: -20℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 3.298 ml 16.492 ml 32.985 ml
5 mM 0.66 ml 3.298 ml 6.597 ml
10 mM 0.33 ml 1.649 ml 3.298 ml
50 mM 0.066 ml 0.33 ml 0.66 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×

相关产品